Login / Register Order My Items
Contact Us
800.227.0627
Contact Us Quote Order Login / Register

Oligonucleotide–Polymer Conjugation Services

Therapeutic-grade conjugation design: loading control, linker engineering, purification, and analytical validation

Custom oligo–polymer conjugation (oligonucleotide polymer conjugation service) for ssDNA/ssRNA, ASO/SSO, and siRNA duplexes — from oligo-PEGylation to synthetic polymers, biodegradable polymers, and dendrimers, with fit-for-purpose QC.

Request a Quote Browse categories
Talk to a chemist Request a quote
Overview Chemistry Select chemistry Categories Therapeutic Related Why us Quality FAQ Reading Contact

Overview

Oligonucleotide–polymer conjugation is the covalent attachment of a synthetic DNA/RNA modality to a polymer chain or polymeric scaffold. Compared with non-covalent association, covalent conjugation enables defined composition, improved reproducibility, and more consistent performance across batches.

Custom polymer and dendrimer conjugation is used to tune solubility, multivalency, biodistribution, and immobilization. Services include oligo-PEGylation, oligo–synthetic polymer conjugation, oligo–biodegradable polymer conjugation, and oligo–dendrimer conjugation for advanced construct design — built with loading control, linker selection, purification, and analytical validation.

We support ssDNA/ssRNA, dsDNA/dsRNA, ASO/SSO, siRNA duplexes, and specialized formats (PNA/PMO project-dependent) with site-defined attachment options and practical data packages.

Oligonucleotide–polymer conjugation overview schematic
Typical planning: choose oligo handle and polymer architecture → select chemistry and linker/spacer → purify → verify with QC aligned to intended use.
What we can control
  • Attachment site: 5′, 3′, and click-ready handles; internal placement is project-dependent
  • Oligo chemistry: PO/PS backbones; 2′-modifications (2′-OMe, 2′-F, MOE, LNA, BNA, cEt, GNA, etc.)
  • Polymer choice: PEG, synthetic polymers (dextran/agarose/PLL and more), biodegradable polymers, dendrimers
  • Spacer/linker: stable vs cleavable designs; spacer length to reduce steric interference
  • Loading targets: degree of substitution / valency control (oligo per polymer; polymer per oligo)
Typical deliverables
  • Purified conjugate (as requested) and COA / data package
  • Conjugate profiling (HPLC/SEC where relevant) and identity checks (LC–MS where applicable/feasible)
  • Documentation aligned to intended use (research, formulation, development‑stage)

Acceptance criteria should be defined by intended use. We will recommend practical analytics based on construct type and polymer distribution.

Oligonucleotide–Polymer Conjugation Categories

Expand each category to view representative items, primary function, and practical application notes.

Focus: Hydrodynamic size tuning & steric shielding

Item Primary function Typical applications / technical notes
Linear mPEG conjugation Increase hydrodynamic radius and steric shielding Baseline strategy for PK modulation and improved handling/solubility; commonly installed via 5′ or 3′ terminal handles (NH2, thiol, or click handles depending on design).
Branched PEG conjugation Higher effective shielding per attachment Provides stronger steric protection at similar or lower apparent size; useful when minimizing chain length while retaining shielding.
Multi-arm PEG (4-arm / 8-arm) Architecture-driven PEG density / multivalency Supports controlled substitution ratios and higher local polymer density; used for advanced construct design and comparative architecture studies.
Monodisperse PEG systems Narrow molecular distribution Improves reproducibility and interpretability for structure–activity and distribution comparisons (best when uniformity is a priority).
Polydisperse PEG systems Cost-efficient screening option Suitable for early-stage screening where exact PEG distribution is not the dominant variable; QC strategy may emphasize profiling rather than exact mass.
Stable PEG linkers Permanent polymer attachment Preferred when long-lived shielding or immobilization is required; linker choice aligned to buffer/handling constraints.
Cleavable PEG linkers Trigger-enabled exposure or release concepts Disulfide, acid-labile, or enzyme-cleavable designs (application-dependent) when polymer removal is part of the experimental hypothesis.
View oligonucleotide-PEGylation

Focus: Non-PEG synthetic scaffolds for multivalency or charge modulation

Item Primary function Typical applications / technical notes
Dextran–oligo conjugates Hydrophilic multivalent scaffold Used for presentation/spacing studies and assay constructs; handle density supports controlled loading concepts.
Agarose–oligo conjugates Immobilization and solid-support formats Capture/pull-down/enrichment workflows (beads/resins); polymer selection driven by binding, washing, and regeneration conditions.
Poly‑L‑lysine (PLL) conjugates Cationic scaffold for charge-driven behavior Delivery-oriented research (electrostatic complexation, uptake studies); substitution ratio and charge balance are key variables.
HPMA copolymer conjugates Polymer–drug style architecture exploration Hydrophilic backbone used for exposure and architecture studies; compatibility depends on available end-groups and MW distribution.
Acrylate/methacrylate polymers Architecture and materials tuning Supports self-assembly/materials concepts; polymer functionality and solvent/buffer constraints guide chemistry choice.
Custom activated synthetic polymers Program-defined scaffolds We evaluate polymer end-group activation (e.g., NHS, maleimide, azide/alkyne) and recommend a route aligned to stability and analytics.
Controlled substitution ratio builds Defined oligo-per-polymer loading Improves reproducibility and interpretability; purification removes free oligo/polymer as appropriate and confirms composition fit-for-purpose.
Explore oligo–synthetic polymer conjugation

Focus: Defined-generation, multivalent architectures

Item Primary function Typical applications / technical notes
PAMAM dendrimer conjugates Defined-generation multivalency Generation (G2–G6+) provides predictable surface group counts for reproducible loading and comparative architecture studies.
PPI dendrimer conjugates Alternative dendritic scaffold Used for multivalency/charge tuning studies; chemistry selection depends on surface amines/handles and desired loading range.
Generation-controlled valency (G2–G6+) Valency and spacing control Enables controlled oligo-per-scaffold targeting; supports interpretable comparisons vs polydisperse scaffolds.
Multivalent oligo display Avidity enhancement / signal amplification Useful for probe architectures and engineered binding formats; substitution ratio is a key design variable.
Charge-density modulation constructs Surface charge tuning Supports uptake/interaction studies; requires careful balancing of oligo loading and dendrimer surface charge.
High-density surface presentation formats Nanoscale assembly architectures High-copy display for materials-like constructs and advanced probe formats; QC often emphasizes distribution and residual free components.

Focus: Controlled degradation & polymer breakdown systems (distinct from trigger-responsive designs)

Item Primary function Typical applications / technical notes
Hydrolytically degradable polymers Time-dependent scaffold breakdown Used for constructs where polymer degradation changes size/exposure over time; selection guided by stability in intended buffers and storage.
Ester-linked polymer systems Common degradable motif Ester-containing backbones support hydrolysis-driven evolution of the conjugate; linker strategy selected to preserve oligo integrity.
Biodegradable backbone conjugates Degradation-governed construct evolution Polymer breakdown can modulate exposure and clearance; analytics often emphasize profiling (distribution/fragmentation) fit-for-purpose.
Controlled release constructs Release via polymer breakdown When the polymer’s degradation rate is part of the design hypothesis; feasibility depends on polymer identity and handle chemistry.
End-group functionalized degradable polymers Site-defined conjugation entry point Improves control vs random attachment; end-group activation (NHS/maleimide/click) selected for compatibility with oligo handle.
Polymer breakdown–linked exposure systems Exposure increases as polymer degrades Distinct from trigger-based systems; designed around passive degradation kinetics rather than environmental triggers.

Focus: Trigger-based environmental response (distinct from passive hydrolysis/biodegradation)

Item Primary function Typical applications / technical notes
pH-responsive polymer conjugates pH-triggered exposure/assembly change Used to explore compartment-dependent behavior; design often includes a triggerable linker or responsive polymer segment.
Redox-responsive systems Reduction-triggered release concepts Often implemented with disulfides (application-dependent); experimental conditions define acceptable stability window.
Enzyme-cleavable linker systems Enzymatic activation Protease/esterase-cleavable motifs used for localized activation concepts; feasibility depends on available chemistry and oligo stability.
Thermo-responsive polymers Temperature-dependent solubility shift Used for formulation/materials and response studies; polymer choice and MW distribution influence transition behavior.
Self-immolative linker constructs Cascade release after trigger Trigger initiates spacer fragmentation and release; project-dependent feasibility and stability assessment required.
Trigger-activated exposure systems General trigger-responsive formats Designed around a defined stimulus (pH/redox/enzyme/thermal); distinct from passive degradation approaches.

Focus: Translational build quality & program alignment

Item Primary function Typical applications / technical notes
Site-defined attachment strategies Reduce heterogeneity Terminal handle placement (5′/3′) helps preserve recognition/hybridization-critical regions; supports reproducible builds.
Substitution ratio control Control composition and distribution Defines oligo-per-polymer loading; improves interpretability and reduces batch-to-batch variability.
Steric shielding optimization Balance stability vs access Polymer size/architecture and attachment site chosen to avoid blocking functional regions; spacer length often critical.
Biodistribution-oriented architecture Tune exposure and disposition Architecture (linear/branched/multi-arm/dendritic) influences size and interaction profiles in model systems.
Exposure tuning builds Iterative optimization Compare architectures under consistent assays to map structure–function relationships; define acceptance criteria early.
Scale-up pathway support Translate methods to larger scale Select robust chemistries, purification, and documentation practices that scale with demand.
Program-aligned QC packages Fit-for-purpose verification HPLC/SEC/UV–Vis composition checks; LC–MS where feasible by construct; reporting aligned to program stage.
Documentation & regulatory-ready formatting Structured data packages Clear build description, COA and reports formatted for efficient review and technology transfer readiness.

Common oligonucleotide–polymer conjugation chemistries

Route selection depends on oligo functional handles, polymer activation chemistry, desired site control, and downstream constraints. Below are commonly used strategies across PEG, synthetic polymers, biodegradable polymers, and dendrimer scaffolds.

Oligonucleotide–polymer conjugation workflow showing handle selection, polymer activation, conjugation, purification, and QC
Typical workflow: define oligo handle and polymer architecture → select chemistry/linker → conjugate → purify → verify with fit-for-purpose QC.
Amine coupling (5′/3′ amine handles)

Typical reagents: NHS-activated polymers; polymer-side carboxyl activation (EDC/NHS concepts)

  • Best for: robust PEG and many activated polymer end-groups
  • Strength: straightforward setup; broad oligo compatibility
  • Note: site definition is achieved by installing a single terminal amine handle
NHS esterAmide linkageTerminal handle
Thiol coupling (5′/3′ thiol handles)

Typical reagents: maleimide polymers; other thiol-reactive end-groups

  • Best for: site-defined constructs when a single thiol handle is installed
  • Strength: high efficiency under mild aqueous conditions
  • Note: linkage stability depends on chemistry and study conditions
MaleimideThiol handleSite-defined
Click chemistry (bioorthogonal)

Handles: azide/alkyne; SPAAC (DBCO/BCN) and CuAAC options (system-dependent)

  • Best for: modular builds and highest selectivity for complex polymer scaffolds
  • Strength: excellent orthogonality and clean site definition
  • Note: requires handle incorporation; copper may be incompatible for some systems
AzideDBCO/BCNModular
Aldehyde/oxime routes (specialized handles)

Concepts: oxime/hydrazone ligations; reductive routes (handle-dependent)

  • Best for: specialized polymer end-groups and custom linker modules
  • Strength: strong site control with appropriate handle design
  • Note: suitability depends on oligo chemistry and polymer system
OximeHydrazoneHandle-dependent
Carboxyl coupling (polymer-side activation)

Typical chemistry: EDC/NHS activation; amide formation to amine-handled oligos

  • Best for: polymers bearing carboxyl groups that require activation
  • Strength: broad applicability to polymer scaffolds
  • Note: site definition comes from a single oligo terminal handle
EDC/NHSPolymer activationBroad
Multivalent scaffolds (dendrimers / polymers)

Concept: control substitution ratio (oligo per polymer) via handle density + stoichiometry

  • Best for: dendrimers (PAMAM/PPI) and multivalent polymer scaffolds
  • Strength: valency control supports reproducibility and interpretability
  • Note: QC focuses on distribution, residual free components, and composition
Valency controlDendriticMultivalent

Select the Right Chemistry

Linkers & spacers (stable vs cleavable)

Spacer length can reduce steric interference and help preserve hybridization/recognition. Cleavable designs are used when a release concept is required (polymer- and application-dependent).

Stable spacers PEG spacers Cleavable linkers (as needed) Hydrolytic / redox / enzyme-sensitive (concept-dependent)
Choosing the right conjugation chemistry

Route selection depends on desired site specificity, linkage stability vs cleavability, polymer end-group chemistry, and downstream constraints (buffers, solvents, analytics).

  • Highest site control: thiol routes or click chemistry
  • Broad, robust builds: terminal amine + NHS-activated polymers
  • Polymer-side activation: EDC/NHS activation for carboxylated scaffolds
  • Release concepts: cleavable linkers and/or degradable polymers (application-dependent)
What to share for fast route selection
  • Oligo sequence + format (ss/ds, ASO, siRNA duplex)
  • Preferred attachment site and handle type (amine / thiol / click)
  • Polymer identity, MW/distribution, and activated end-group chemistry
  • Stability requirements (stable vs cleavable linker)
  • Target scale and required QC/data package

We will recommend a practical route and fit-for-purpose verification plan based on these inputs.

Oligo–polymer conjugates for therapeutic development

Therapeutic oligonucleotide–polymer conjugation is strategically applied to modulate pharmacokinetics (PK), hydrodynamic radius, steric shielding, biodistribution, and exposure kinetics in antisense oligonucleotide (ASO), siRNA, and duplex RNA development programs. Polymer-conjugated oligonucleotides are evaluated for renal clearance reduction, multivalent architecture design, degradation-controlled exposure, and structure–function mapping in translational-stage research.

Therapeutic Oligonucleotide–Polymer Conjugation Architecture showing PEGylated ASO constructs, siRNA–polymer conjugates, dendrimer multivalent display, and biodegradable polymer-linked oligonucleotides

Representative therapeutic architectures illustrating PEGylated ASO constructs, siRNA–polymer conjugates, dendrimer multivalent display, and biodegradable polymer-linked oligonucleotides.

Design goals we commonly support
  • Exposure/PK tuning: polymer MW/architecture and attachment site selection
  • Biodistribution considerations: steric shielding vs target engagement trade-offs
  • Release concepts: cleavable linkers or degradable polymers where appropriate
  • Formulation: improved solubility and stability for handling and dosing
  • Multivalency: controlled loading for avidity and architecture studies
Analytics and documentation
  • Purity/profile: HPLC/UPLC; SEC where relevant
  • Identity: LC–MS where applicable/feasible; method depends on polymer system
  • Composition: UV/Vis or ratio methods for loading estimates
  • Stability: fit-for-purpose checks aligned to intended storage/use
  • Documentation: COA and method summary; program-aligned acceptance criteria

Polymer polydispersity can influence analytical strategy; we will recommend practical verification methods.

Technical Design Guidance for Therapeutic Oligonucleotide–Polymer Conjugates

Attachment Site Selection: 5′ vs 3′ modification is selected based on preservation of hybridization-critical domains and RISC-loading compatibility (siRNA context). Internal modification may be considered for architecture-driven studies where terminal functionality must remain unaltered.

Polymer Molecular Weight (MW): Hydrodynamic diameter scales with polymer MW and architecture (linear vs branched vs dendritic). Excessive shielding may reduce target accessibility; spacer optimization mitigates steric interference.

Substitution Ratio Control: Defined oligo-per-polymer loading improves reproducibility and interpretability in PK and exposure studies. Stoichiometric control and purification strategy are critical to minimize unconjugated species.

Linker Stability Engineering: Stable linkers (amide, thioether) are used when permanent shielding is required. Cleavable motifs (disulfide, acid-labile, enzyme-responsive) are selected when controlled release or exposure evolution is part of the development hypothesis.

Analytical Considerations: Characterization may include RP-HPLC, SEC-HPLC, LC–MS (when feasible), UV-based loading quantification, and distribution profiling. Polymer polydispersity influences analytical resolution and reporting strategy.

Why Bio‑Synthesis for Oligo–Polymer Conjugation?

Oligo-first design (not “polymer only”)
  • Handle planning: we can incorporate functional handles during oligo synthesis for cleaner conjugation
  • Site control: prefer site-defined strategies when activity or reproducibility is critical
  • Linker selection: stable spacers and cleavable designs when a release concept is required
  • Loading control: practical targeting of substitution ratio/valency for multivalent scaffolds
Fit-for-purpose QC and documentation
  • Characterization: HPLC/UPLC profiling; SEC when relevant; LC–MS where applicable/feasible
  • Reproducibility: defined workflows to support consistent performance across batches
  • Communication: practical recommendations on buffers, starting materials, and success criteria

Share intended use and acceptance criteria (research, formulation, development‑stage) so we can match chemistry and data package.

What we typically need to quote accurately
Oligo sequence & format Handle & attachment site Polymer type & MW/distribution Target loading Scale QC/data package

Our Quality Commitment

We are committed to Total Quality Management (TQM) across all oligonucleotide synthesis, modification, and oligo–polymer conjugation services. Our quality systems are designed to ensure consistency, traceability, and customer confidence from early research through development‑stage programs.

Oligo–polymer conjugates are produced using controlled procedures with defined inputs, documented workflows, and in-process controls. Final release testing is selected based on intended use and polymer system complexity.

  • Purity & profiling: analytical HPLC/UPLC; SEC-HPLC when relevant to polymer or PEG distribution
  • Identity confirmation: LC–MS when feasible (method suitability depends on polymer system)
  • Process transparency: clear reporting of conjugation strategy, yield, and limitations
  • Documentation: Certificate of Analysis (COA) and method summary aligned to project stage

Our quality practices follow ISO 9001–aligned processes, with scalable controls to support research, preclinical, and GMP programs as required.

FAQ

Do you offer site-defined oligo–polymer conjugation?

Yes. We support site-defined attachment using 5′/3′ terminal handles (amine, thiol, azide/alkyne), with chemistry selected for your polymer end-group and desired control.

Can you work with monodisperse and polydisperse polymer reagents?

Yes. We can work with monodisperse (narrow distribution) or polydisperse polymer reagents when available. Analytical strategy may differ depending on polymer distribution and construct type.

What polymer information do you need to start?

For quoting and route selection, please provide polymer identity, molecular weight (or range/distribution), end-group activation chemistry, solvent/buffer constraints, and desired oligo attachment site/handle type.

What QC and documentation are provided?

Fit-for-purpose QC typically includes HPLC/UPLC profiling and, where applicable, LC–MS identity confirmation. Additional methods such as SEC may be used when relevant to polymer distribution or aggregation behavior.

More FAQ'sAll FAQ's

Request a quote

What to send
  • Oligo sequence and format (ss/ds, ASO, siRNA duplex)
  • Desired handle/attachment site (5′/3′/constraints)
  • Polymer identity, MW/distribution, and end-group chemistry
  • Target scale and required deliverables (purification/QC/documentation)
  • Buffer/solvent constraints and intended use (research/formulation/development‑stage)
Next steps

Share your inputs and timeline. We’ll recommend a practical conjugation route and a fit-for-purpose verification plan.

Request a Quote Contact

Recommended Reading

Background references for planning polymer conjugation strategies and characterization.

  • Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008.
  • Knop K et al. Poly(ethylene glycol) in drug delivery: pros and cons. Angew Chem Int Ed. 2010.
  • Prakash TP. An overview of sugar-modified oligonucleotides for antisense therapeutics. Chem Biodivers. 2011.
  • Judge AD et al. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther. 2006.
  • Hermanson, G. T. Bioconjugate Techniques (3rd ed.). Book listing
  • PEGylation and polymer–drug conjugate design (general concepts). Search PubMed
  • Dedicated platform pages for internal linking depth: Oligo-PEGylation, Oligo–Synthetic Polymer, Oligo–Dendrimer.

References are provided for scientific context. Acceptance criteria and release tests should be defined per intended use.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links